Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells

NCT02045745 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-03-30

No results posted yet for this study

Summary

The purpose of this study is to analyze the safety and feasibility of the implantation of autologous mesenchymal stem cells (MSCs) expanded "in vitro" and administered directly in the lung line of suture as a treatment for patients at risk of postoperative air leaks after lung resection.

Conditions

  • Postoperative Air Leaks in Risk Patients

Interventions

BIOLOGICAL

Implantation of autologous mesenchymal stem cells (CSM) expanded "in vitro" and administered directly into the lung suture line

Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro

Sponsors & Collaborators

  • Castilla y León Hematology and hemotherapy Foundation

    collaborator UNKNOWN
  • Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán

    collaborator OTHER
  • Spanish National Health System

    collaborator OTHER
  • Red de Terapia Celular

    lead INDUSTRY

Principal Investigators

  • Marcelo F Jiménez López, Ph.D · University Clinical Hospital of Salamanca

  • Gonzalo Varela Simó, Ph.D · University Clinical Hospital of Salamanca

  • Nuria M Novoa Valentín, Ph.D · University Clinical Hospital of Salamanca

  • José L Aranda Alcaide, Ph.D · University Clinical Hospital of Salamanca

  • Consuelo del Cañizo, Ph.D · University Clinical Hospital of Salamanca

  • Fermín Sánchez-Guijo Martín, Ph.D · University Clinical Hospital of Salamanca

  • Olga López Villar, Ph.D · University Clinical Hospital of Salamanca

  • Eva M Villarón Ríos, Ph.D · University Clinical Hospital of Salamanca

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02045745 on ClinicalTrials.gov